Karina Vázquez-Arreguín

Biochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation”.

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation

Molecular Therapy — Oncolytics(2023)10.1016/j.omto.2023.01.003

N/A

0DataRank · unranked

9 citations

Ji Seon Shim, Kimberly Rivera-Caraballo, Karina Vázquez-Arreguín, Bangxing Hong, Alberto J Bueso-Perez +5 more

TMIC-61. DEVELOPMENT OF A NOVEL NOTCH-TARGETING ONCOLYTIC HSV FOR GBM TUMORS

Neuro-Oncology(2024)10.1093/neuonc/noae165.1239

N/A

0DataRank · unranked

0 citations

Yoshihiro Otani, Kimberly Rivera-Caraballo, Balveen Kaur, Karina Vázquez-Arreguín

Oncolytic HSV and cancer drug interactions: Current clinical status and future directions

Molecular Therapy(2025)10.1016/j.ymthe.2025.07.034

N/A

0DataRank · unranked

10 citations

Kimberly Rivera-Caraballo, Divya Ventarapragada, E Antonio Chiocca, Balveen Kaur, Karina Vázquez-Arreguín